Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1195-1204

  Lister, Nicola ^a   Warrington, Steve ^a   Boyce, Malcolm ^a   Eriksson, Catarina ^b   Tamaoka, Masami ^c   Kilborn, John ^c  

^a Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^b IQVIA   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

fentanyl; Japanese; naltrexone; pharmacokinetics; Sublingual

Indexed keywords

FENTANYL; KW 2246; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATHING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; EUPHORIA; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRURITUS; PULSE OXIMETRY; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH DISCOMFORT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCUTANEOUS CARBON DIOXIDE MONITORING; VOMITING;

ABSORPTION; ADMINISTRATION, SUBLINGUAL; ADULT; ANALGESICS, OPIOID; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GAS MONITORING, TRANSCUTANEOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; FENTANYL; HALF-LIFE; HUMANS; JAPAN; MALE; MOUTH MUCOSA; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU; RESPIRATORY INSUFFICIENCY; TABLETS; YOUNG ADULT;

EID: 79960712673     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010379410     Document Type: Article

References (23)

1. Stanley TH. Fentanyl. J Pain Symptom Manage. 2005 ; 29: S67 - S71
2. Gutstein HB, Akil H Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11 th ed. New York, NY: McGraw-Hill ; 2006 :
3. Cephalon UK Ltd. Actiq Monograph. 2006; Cephalon UK Ltd, Guildford, Surrey, UK (page 6). www.actiq.co.uk/downloads/Actiq-Monograph.pdf. Accessed June 10, 2009.
4. Casuccio A, Mercadante S, Fulfaro F. Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother. 2009 ; 10: 947-953
5. Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005 ; 44: 1279-1286 (Pubitemid 41832568)
6. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy and drug interactions. Drug Metab Dispos. 1997 ; 25: 1072-1080 (Pubitemid 27396495)
7. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology. 1998 ; 88: 305-309 (Pubitemid 28081188)
8. Egan TD, Sharma A, Ashburn MA, Kievit J, Pace NL, Streisand JB. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology. 2000 ; 92: 665-673 (Pubitemid 30130168)
9. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther. 2006 ; 28: 707-714 (Pubitemid 44067265)
10. Darwish M, Kirby M, Robertson P, Hellriegel E, Jiang JG. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J Clin Pharmacol. 2007 ; 47: 56-63 (Pubitemid 44973998)
11. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig. 2007 ; 27: 605-611 (Pubitemid 47295719)
12. Lennernäs B, Hedner T, Holmberg M, Bredenberg S, Nyström C, Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2004 ; 59: 249-253 (Pubitemid 40208864)
13. Lorch U, Farrell F, Kilborn J, Tamaoka M, Derrick R, Howell J.. Paper presented at: 13th International Pain Clinic Congress, World Society of Pain Clinicians ; Seoul, Korea ;..
14. Galashiels, UK: ProStrakan Ltd ; 2008 :
15. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008 ; 84: 347-361
16. Shou W, Jiang X, Beato B, Naidong W. A highly automated 96-well solid phase extraction and liquid chromatography/tandem mass spectrometry method for the determination of fentanyl in human plasma. Rapid Commun Mass Spectrom. 2001 ; 15: 466-476 (Pubitemid 32294642)
17. Mountain View, Calif: Pharsight Corporation ;
18. Gupta SK, Sathyan G, Phipps B, Klausner M, Southam M. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci. 1999 ; 8: 835-841 (Pubitemid 29398554)
19. Gupta SK, Bernstein KJ, Noorfuin H, et al. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. Am J Clin Pharm. 1998 ; 38: 951-958 (Pubitemid 28482122)
20. Mildh LH, Scheinin H, Kirvelä OA. The concentration-effect relationship of the respiratory depressant effects of alfentanil and fentanyl. Anesth Analg. 2001 ; 93: 939-946 (Pubitemid 32905983)
21. Stanley TH, Hague B, Mock DL, et al. Oral transmucosal fentanyl citrate (lollipop) premedication in human volunteers. Anesth Analg. 1989 ; 69: 21-27 (Pubitemid 20037059)
22. Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology. 2004 ; 101: 738-743 (Pubitemid 39121654)
23. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009 ; 25: 2877-2885